PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739191
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739191
m-RNA Synthesis Services
Global m-RNA Synthesis Services Market to Reach US$10.0 Billion by 2030
The global market for m-RNA Synthesis Services estimated at US$7.3 Billion in the year 2024, is expected to reach US$10.0 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Therapeutic Development Application, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Vaccine Production Application segment is estimated at 4.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 5.1% CAGR
The m-RNA Synthesis Services market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.9% and 4.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.
Global m-RNA Synthesis Services Market - Key Trends & Drivers Summarized
Why Are m-RNA Synthesis Services Becoming a Cornerstone in Next-Generation Therapeutics and Vaccine Platforms?
Messenger RNA (mRNA) synthesis services are rapidly evolving into a foundational pillar of the biopharmaceutical ecosystem, particularly in the wake of global attention on mRNA-based COVID-19 vaccines. mRNA functions as the transient intermediary between DNA and protein synthesis, making it a versatile vehicle for encoding disease-specific proteins in therapeutic applications. The demand for high-purity, GMP-grade synthetic mRNA is growing across vaccine development, personalized cancer immunotherapy, protein replacement therapies, and rare disease treatments.
Unlike traditional protein or viral vector-based therapeutics, mRNA-based modalities offer rapid, scalable, and cell-free manufacturing advantages. Their ability to elicit targeted immune responses without the risk of genome integration has opened up new possibilities in infectious disease prevention and oncology. Consequently, drug developers-especially biotech startups and academic consortia-are increasingly outsourcing mRNA synthesis to specialized contract development and manufacturing organizations (CDMOs) that provide optimized transcription protocols, capping technologies, and downstream purification expertise.
How Are Technology Platforms and Process Innovations Accelerating the Evolution of m-RNA Synthesis Services?
The technological landscape of mRNA synthesis is advancing rapidly through innovations in in vitro transcription (IVT) chemistry, enzymatic capping, and sequence optimization. Synthetic DNA templates are transcribed using phage RNA polymerases (e.g., T7, SP6), with improvements in template engineering enhancing stability, translational efficiency, and immune evasion. Modified nucleosides like pseudouridine and 5-methylcytidine are being incorporated to reduce innate immune responses and improve mRNA longevity post-administration.
Cap analogs (such as CleanCap and ARCA) and poly(A) tail length optimization are now routinely integrated into synthesis workflows, improving ribosome recruitment and translation fidelity. CDMOs are offering end-to-end services-including plasmid linearization, IVT reaction, DNase treatment, chromatographic purification, and sterile fill-finish-under GMP or research-use conditions. The integration of automation, single-use bioreactors, and AI-based quality analytics is reducing cycle times, increasing batch consistency, and ensuring compliance with regulatory expectations for nucleic acid therapeutics.
Which Therapeutic Areas and Developer Segments Are Driving Demand for m-RNA Synthesis Services Globally?
Infectious diseases remain the most prominent therapeutic application, particularly with the success of mRNA vaccines for COVID-19 by Moderna and Pfizer-BioNTech. However, oncology is fast emerging as the next frontier, with mRNA being used to encode tumor-specific neoantigens for individualized immunotherapy. Research is also expanding into cardiovascular diseases, autoimmune conditions, metabolic disorders, and genetic deficiencies-where mRNA can be programmed to express functional proteins in vivo, offering transient but potent therapeutic effects.
Academic labs, small biotech firms, and mRNA-focused startups are the most active clients of synthesis service providers due to limited in-house GMP capabilities and the high cost of cleanroom biomanufacturing infrastructure. In parallel, large pharmaceutical companies are increasingly partnering with CDMOs to expand their mRNA pipelines, leveraging external expertise in nucleic acid synthesis, scale-up, and formulation. Government agencies and public-private partnerships are also fueling demand through vaccine stockpile development and pandemic preparedness initiatives.
What Is Driving Long-Term Growth and Competitive Differentiation in the m-RNA Synthesis Services Market?
The growth in the mRNA synthesis services market is driven by the expanding application scope of mRNA-based therapeutics, growing VC investment in mRNA startups, and increasing acceptance of nucleic acid-based modalities by regulatory agencies. Global regulatory frameworks are being adapted to fast-track mRNA candidates under breakthrough therapy and accelerated approval pathways, encouraging development and outsourcing activity. The rise of personalized medicine and neoantigen-specific cancer therapies is fostering a surge in demand for small-batch, customized mRNA synthesis services.
To differentiate in a competitive market, service providers are focusing on platform scalability, IP-protected cap analogs, GMP compliance, and integration with lipid nanoparticle (LNP) formulation services. Some are vertically integrating into DNA template manufacturing and RNA stabilization technologies to offer full-cycle RNA drug development support. As mRNA transitions from emergency vaccine use to mainstream therapeutic applications, robust, reliable, and regulatory-compliant synthesis services will be essential to accelerating innovation and ensuring commercial success in this high-growth segment.
SCOPE OF STUDY:
The report analyzes the m-RNA Synthesis Services market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Application (Therapeutic Development, Vaccine Production, Drug Discovery, Other Applications); Scale of Operation (Research, Commercial); End-User (Biopharmaceutical Companies, Contract Research Organizations, Other End-Users)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 44 Featured) -
- AGC Biologics
- Aldevron
- APExBIO
- Aurigene Pharmaceutical Services
- Biomay
- BioNTech SE
- CELLSCRIPT
- Creative Biogene
- CureVac N.V.
- Eurofins Genomics
- GENEWIZ (Azenta Life Sciences)
- GenScript
- Integrated DNA Technologies
- Merck KGaA
- Moderna, Inc.
- New England Biolabs
- Samsung Biologics
- ST Pharm
- Thermo Fisher Scientific
- TriLink BioTechnologies
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- m-RNA Synthesis Services - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Investment in mRNA Therapeutics and Vaccines Drives Demand for Scalable Synthesis Services
- Expansion of RNA-Based Drug Development Pipelines Throws the Spotlight on Outsourced mRNA Manufacturing
- Advancements in In Vitro Transcription Technologies Strengthen Process Efficiency and Purity Levels
- Growth in Personalized Cancer Immunotherapy and Rare Disease Therapies Fuels Use of Custom mRNA Constructs
- Increased Demand for GMP-Compliant and Clinical-Grade mRNA Production Supports Biopharma Outsourcing
- Use of Enzymatic Capping, Polyadenylation, and Purification Enhances Bioavailability and Stability
- Surge in COVID-19 and Pandemic-Preparedness Initiatives Accelerates Infrastructure for Rapid Response mRNA Platforms
- OEM Collaborations With CDMOs and CROs Drive Standardization of mRNA Workflows
- Expansion of Synthetic Biology and Modular Plasmid Engineering Supports Multi-Payload Expression Platforms
- Focus on Scalable In-House Bioreactor and Cell-Free Systems Improves Turnaround for Clinical Trials
- Use of Lipid Nanoparticle (LNP) and Other Delivery-Compatible Formulations Expands Downstream Integration
- Regulatory Acceleration and Emergency Use Approvals Strengthen Market Entry for mRNA-Based Products
- Increased Biotech Startups' Reliance on Contract Synthesis Supports One-Stop mRNA Development Models
- Focus on High-Fidelity and Sequence-Specific Synthesis Reduces Batch Variability and Contamination Risk
- Growth in Therapeutic Areas Including HIV, Malaria, Zika, and CMV Expands End-Use Base
- Government Funding and Pandemic Security Programs Drive Investment in Regional Synthesis Facilities
- Emergence of Self-Amplifying and Circular RNA Variants Spurs Diversification in Synthesis Capabilities
- Emphasis on IP Licensing, Codon Optimization, and Proprietary Templates Strengthens Competitive Differentiation
- Rising Demand for Cell Therapy and Gene Editing Tools Expands Role of mRNA in CRISPR Delivery
- Digital Twin and Automation Technologies Enhance Precision and Throughput in Custom Synthesis Workflows
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World m-RNA Synthesis Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for m-RNA Synthesis Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for m-RNA Synthesis Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Therapeutic Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Therapeutic Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Therapeutic Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Vaccine Production by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Vaccine Production by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Vaccine Production by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Commercial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 32: USA Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: USA Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: USA 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 35: USA Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: USA Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: USA 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 38: USA Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: USA Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: USA 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- CANADA
- TABLE 41: Canada Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Canada Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Canada 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 44: Canada Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Canada Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Canada 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 47: Canada Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Canada Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Canada 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- JAPAN
- m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 50: Japan Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Japan Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Japan 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 53: Japan Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Japan Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Japan 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 56: Japan Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Japan Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Japan 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- CHINA
- m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 59: China Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: China Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: China 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 62: China Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: China Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: China 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 65: China Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: China Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: China 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- EUROPE
- m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 68: Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 69: Europe Historic Review for m-RNA Synthesis Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Europe 15-Year Perspective for m-RNA Synthesis Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 71: Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Europe Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Europe 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 74: Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Europe Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Europe 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 77: Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Europe Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Europe 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- FRANCE
- m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 80: France Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: France Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: France 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 83: France Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: France Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: France 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 86: France Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: France Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: France 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- GERMANY
- m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 89: Germany Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Germany Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Germany 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 92: Germany Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Germany Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Germany 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 95: Germany Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Germany Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Germany 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- ITALY
- TABLE 98: Italy Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Italy Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Italy 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 101: Italy Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Italy Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Italy 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 104: Italy Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Italy Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Italy 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 107: UK Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: UK Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: UK 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 110: UK Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: UK Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: UK 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 113: UK Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: UK Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: UK 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: Rest of Europe Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: Rest of Europe 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: Rest of Europe Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: Rest of Europe 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: Rest of Europe Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: Rest of Europe 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Asia-Pacific Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Asia-Pacific 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Asia-Pacific Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: Asia-Pacific 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Asia-Pacific Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Asia-Pacific 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
- REST OF WORLD
- TABLE 134: Rest of World Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Rest of World Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Rest of World 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
- TABLE 137: Rest of World Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Rest of World Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Rest of World 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
- TABLE 140: Rest of World Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Rest of World Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Rest of World 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
IV. COMPETITION
